GlycoMimetics, Inc. (renamed Crescent Biopharma, Inc., June 2025)
CBIO · Nasdaq · United States
Share price · CBIO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CBIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Sep 2026-13.7%
Nothing announced by CBIO that day or the session before.
- 16 Sep 2026-8.6%
Nothing announced by CBIO that day or the session before.
- 3 Sep 2026+10.0%
Nothing announced by CBIO that day or the session before.
- 1 May 2026-19.2%
Nothing announced by CBIO that day or the session before.
- 21 Apr 2026+13.3%
Nothing announced by CBIO that day or the session before.
- 27 Mar 2026+12.3%
Nothing announced by CBIO that day or the session before.
- 26 Mar 2026+14.6%
Nothing announced by CBIO that day or the session before.
- 19 Feb 2026+20.8%
Nothing announced by CBIO that day or the session before.
- 26 Jan 2026-8.2%
Nothing announced by CBIO that day or the session before.
- 16 Jan 2026+8.1%
Nothing announced by CBIO that day or the session before.
Share of unusual movement by asset
For each asset, the share of CBIO's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
CR-001events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 4% |
| Sessions with no dated event | — | 96% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | PD-1 + VEGFMultispecific antibody | Solid Tumors |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $3.1M | $34M | $289M | $38M-$27M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $19M | $172M | $25M-$19M operating cash flow | report ↗ |
| 2026-Q1 | — | $18M | $189M | $23M-$8.9M operating cash flow | report ↗ |
| 2025-Q4 | — | — | $213M | $23M-$27M operating cash flow | report ↗ |
| 2025-Q3 | — | $20M | $133M | $25M-$18M operating cash flow | report ↗ |
| 2025-Q2 | — | $12M | $153M | $22M-$22M operating cash flow | report ↗ |
| 2025-Q1 | — | <$0.1M | $5.6M | $2.3M-$5.1M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.7M | $14M | $9.8M-$8.0M operating cash flow | report ↗ |
| 2024-Q2 | — | $6.3M | $22M | $10M-$8.9M operating cash flow | report ↗ |
| 2024-Q1 | — | $6.0M | $31M | $11M-$11M operating cash flow | report ↗ |
| 2023-Q3 | — | $5.3M | $49M | $9.2M-$8.7M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.1M | $58M | $8.3M-$7.0M operating cash flow | report ↗ |
| 2023-Q1 | — | $5.4M | $65M | $10M-$12M operating cash flow | report ↗ |
| 2022-Q3 | — | $4.9M | $52M | $8.5M-$8.6M operating cash flow | report ↗ |
| 2022-Q2 | $0.1M | $8.0M | $60M | $13M-$16M operating cash flow | report ↗ |
| 2022-Q1 | — | $9.6M | $77M | $15M-$14M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $13M | $102M | $17M-$17M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $138M | $213M | $38M-$72M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($30.6M), 16 sales ($1.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-18 | McNeill Jonathan · President and COO | Open-market sale | 3,839 | $16.71 | $64K | Form 4 |
| 2026-09-18 | Brumm Joshua T · director, Chief Executive Officer | Open-market sale | 7,837 | $16.71 | $131K | Form 4 |
| 2026-09-16 | McNeill Jonathan · President and COO | Open-market sale | 731 | $17.90 | $13K | Form 4 |
| 2026-09-16 | Brumm Joshua T · director, Chief Executive Officer | Open-market sale | 1,610 | $17.90 | $29K | Form 4 |
| 2026-09-16 | Bispham Barbara Harlin · See Remarks | Open-market sale | 620 | $17.90 | $11K | Form 4 |
| 2026-09-16 | Scalzo Richard William · Chief Financial Officer | Open-market sale | 568 | $17.90 | $10K | Form 4 |
| 2026-09-16 | Im Ellie Eunkyung · Chief Medical Officer | Open-market sale | 623 | $17.90 | $11K | Form 4 |
| 2026-09-16 | Pinkas Jan · Chief Scientific Officer | Open-market sale | 658 | $17.90 | $12K | Form 4 |